for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SIGA Technologies, Inc.

SIGA.OQ

Latest Trade

5.01USD

Change

-0.00(-0.00%)

Volume

78,481

Today's Range

4.96

 - 

5.07

52 Week Range

4.92

 - 

8.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.01
Open
5.00
Volume
78,481
3M AVG Volume
2.93
Today's High
5.07
Today's Low
4.96
52 Week High
8.07
52 Week Low
4.92
Shares Out (MIL)
81.07
Market Cap (MIL)
411.86
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 SIGA Technologies Inc Earnings Release

Latest Developments

More

Siga Announces TPOXX Promotion Agreement With Meridian Medical Technologies For International Markets

Siga Technologies Awarded BARDA Contract For TPOXX

U.S. FDA Approves Siga Technologies’ Tpoxx (Tecovirimat) For Treatment Of Smallpox

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SIGA Technologies, Inc.

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company's lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Industry

Biotechnology & Drugs

Contact Info

31 E 62nd St

+1.212.6729100

https://www.siga.com/

Executive Leadership

Eric A. Rose

Chairman of the Board

Phillip Louis Gomez

Chief Executive Officer, Director

Daniel J. Luckshire

Chief Financial Officer, Executive Vice President, Secretary

Robin E. Abrams

Chief Administrative Officer, General Counsel

Dennis E. Hruby

Chief Scientific Officer, Vice President

Key Stats

Price To Earnings (TTM)
8.19
Price To Sales (TTM)
17.13
Price To Book (MRQ)
4.00
Price To Cash Flow (TTM)
8.23
Total Debt To Equity (MRQ)
76.71
LT Debt To Equity (MRQ)
76.71
Return on Investment (TTM)
30.12
Return on Equity (TTM)
28.64

Latest News

Latest News

BRIEF-SIGA Technologies Says Panel Voted Unanimously, That Benefits Of TPOXX Outweigh Risks

* SIGA TECHNOLOGIES ANNOUNCES FAVORABLE OUTCOME OF ADVISORY COMMITTEE IN SUPPORT OF TPOXX®

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up